Phase I Trial: Quotient Code QSC301789
This clinical trial, known as Quotient Code QSC301789, is a very early-stage study (Phase I) of a new treatment. At this moment, the full details about what the treatment is and what condition it's aiming to help with are not available to the public. This is a common practice for some new studies, and all the information will be published within 30 months after the study has finished. The trial is open to adults between 18 and 55 years old, including both men and women. The main goal of a Phase I trial is usually to check if a new treatment is safe and to find the right dose. More information about who can take part (eligibility) will also be released at the same time. We will update this information as soon as it becomes available.
At a glance
What is this study about?
This is an early-stage medical study, which scientists call a 'Phase I' trial. The study has a name: Quotient Code QSC301789. The main purpose of these early studies is to check if a new treatment is safe for people and to figure out what dose works best without causing too many problems. It's an important step for any new medicine before it can be studied in larger groups of people.
At the moment, the detailed information about what this new treatment is, what it's trying to achieve, and the specific health conditions it might be for, isn't publicly available. This often happens with very new research. All these details will be shared and added to the study's record up to 30 months after the trial has been completed. This waiting period allows the researchers and the company sponsoring the study to gather and process all their findings properly.
Even though we don't have all the specifics yet, you can be reassured that any medical trial follows strict rules to protect the people who take part. Once the full details are released, we will update this information to give you a clearer picture of what this study involves and why it's important for medical science.
Key takeaways
- This is an early-stage safety study of a new treatment.
- Full details about the treatment and condition are not yet public.
- Details will be shared within 30 months after the study finishes.
- Open to adults aged 18 to 55, both men and women.
- Participation involves monitoring for safety and understanding how the new treatment works.
Who may be eligible?
Currently, we don't have all the specific details about who can and cannot join this study. This information, including the particular health conditions or circumstances that would make someone suitable or unsuitable to take part, will be made public later on.
However, we do know that the study is looking for adults. Participants must be between 18 and 55 years old, and both men and women can consider taking part.
When the full details are released, they will include important criteria like specific medical tests, current health status, and any medications you might be taking. These are all checked carefully to make sure the study is safe for everyone involved and that the results are as clear as possible.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you between 18 and 55 years old?
- Are you willing to discuss your full medical history with the study team?
- Are you available for potential regular clinic visits?
- Are you comfortable potentially receiving an experimental treatment?
What does participation involve?
Because the full details of this study are not yet public, we can't give specific information about what taking part would involve. Generally, in a Phase I study like this, participation could include:
* **Visits to the clinic:** These might be frequent at the beginning and then less often later. * **Assessments:** You would likely have various tests, such as blood samples, physical exams, and possibly scans, to check your health and how your body is reacting to the treatment. * **Medication:** You would receive the new treatment being tested, likely in a specific dose chosen by the study team. * **Follow-up:** After receiving the treatment, there would be follow-up appointments to monitor your health and any effects of the treatment. * **Total duration:** The entire commitment for a Phase I study can vary, but it's often over several weeks to a few months. Once the detailed information is released, we will be able to provide a much clearer picture of what would be expected of participants.
Potential risks and benefits
Locations (1)
- Quotient Sciences LimitedCity onlyNottingham, United Kingdom
Common questions
What is a 'Phase I' trial?
It's the very first stage of testing a new treatment in humans. Scientists check if it's safe, how it acts in the body, and what dose might be best.
Why aren't all the study details available yet?
For some new studies, the full details are kept private temporarily. They will be published within 30 months after the study is finished.
Who can take part in this study?
Adults between 18 and 55 years old, both men and women, are eligible. More specific requirements will be released later.
Will I know if the treatment is helping me?
In Phase I studies, the focus is on safety, not necessarily on if the treatment helps your condition. Any effects will be monitored and discussed with you.
Can I leave the study if I change my mind?
Yes, absolutely. You have the right to withdraw from the study at any point, and it will not affect your usual medical care.
How to find out more
Clinical Trials Information
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.